Drugs › Vascular endothelial growth factor inhibitor
Brand name · Ziv-aflibercept
Zaltrap: adverse event reports filed with FDA
1,227 reports list it as a suspect or interacting product, 2012–2026. Class: Vascular endothelial growth factor inhibitor. Also reported as Zaltrap /06225401/.
- 1,227
- reports as suspect product
- 0% of all reports · about 89 a year
- 22
- reports, 12 months to June 2026
- 14 in the 12 months before
- 93.3%
- marked serious by the reporter
- 87.6% across the class
- 16%
- record death among outcomes, as reported
- 196 reports · not verified by FDA
Between September 2012 and June 2026, 1,227 adverse event reports received by FDA list the brand name Zaltrap (ziv-aflibercept) as a suspect or interacting product. Reports that mention it only as a concomitant medication (59) are left out of every figure here.
In the 12 months to June 2026, 22 reports listed it, up 57% from 14 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 89 reports a year and 0% of the 20,646,523 reports in the database, and 0.7% of the reports for the vascular endothelial growth factor inhibitor class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded diarrhoea (13.9%), hypertension (10.8%) and neutropenia (7.9%). A report can list several reactions, so shares add to more than 100%; 316 different terms appear across these reports. Diarrhoea is recorded in 13.9% of these reports, a larger share than in the median vascular endothelial growth factor inhibitor drug (2.2%).
93.3% of the reports are marked serious by the reporter (87.6% across the class); 16% record death among the outcomes and 46% record hospitalisation, as reported. 56.8% of the reports came from physicians, and the largest patient age group is 45 to 64 (32.1%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Zaltrap reports recording the termmedian drug in vascular endothelial growth factor inhibitor
- Diarrhoealoose or frequent stools13.9%170
- Hypertensionhigh blood pressure10.8%133
- Neutropenialow neutrophils, a type of white blood cell7.9%97
- Astheniaweakness or lack of energy5.3%65
- Proteinuriaprotein in the urine5.1%62
- Deaththe patient died; cause not stated by this term4.8%59
- Vomitingbeing sick4.7%58
- Nauseafeeling sick4.2%51
- Disease progressionthe disease advanced3.3%41
- Abdominal painstomach or belly pain3.3%40
- Fatiguetiredness3.1%38
- Stomatitissore mouth3.1%38
- Pyrexiafever3%37
- Febrile neutropeniafever with low white blood cells2.9%35
- Neuropathy peripheralnerve damage in hands or feet2.9%35
- Decreased appetitereduced appetite2.7%33
- Dyspnoeashortness of breath2.6%32
- Dysphoniaa hoarse voice2.3%28
- Thrombocytopenialow platelets2.3%28
- Epistaxisnosebleed2.2%27
- Headachehead pain2.1%26
- Malaisegeneral feeling of being unwell2.1%26
- Mucosal inflammation2.1%26
- Alopeciahair loss2%25
- Pneumonialung infection2%25
- Pulmonary embolisma blood clot in the lung2%25
- Anaemialow red blood cells1.9%23
- Condition aggravatedthe condition being treated got worse1.9%23
- Rectal haemorrhage1.9%23
Top 30 of 316 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 10 drugs in the vascular endothelial growth factor inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 176,429 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 17.7% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Colorectal cancer metastatic | 254 | 20.7% |
| Colon cancer | 177 | 14.4% |
| Rectal cancer | 77 | 6.3% |
| Colorectal cancer | 72 | 5.9% |
| Adenocarcinoma of colon | 69 | 5.6% |
| Colon cancer metastatic | 60 | 4.9% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,227 reports.
In context
| Measure | Zaltrap | Vascular endothelial growth factor inhibitor | All reports |
|---|---|---|---|
| Reports as suspect product | 1,227 | 176,429 | 20,646,523 |
| Share of that pool | — | 0.7% | 0% |
| Reports, latest 12 months | 22 | — | 1,332,454 |
| Marked serious | 93.3% | 87.6% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 160 | 237 | 91 |
| Hospitalisation recorded, per 1,000 reports | 460 | 269 | 213 |
| Consumer-filed share | 4.8% | 24.9% | 45.8% |
| Top term, share of reports | Diarrhoea 13.9% | median 2.2% | 3.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the vascular endothelial growth factor inhibitor class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Avastin | brand | 60,510 | 2,198 | 87.3% |
| Bevacizumab | generic | 54,611 | 6,049 | 96.4% |
| Eylea | brand | 25,826 | 968 | 81.5% |
| Lucentis | brand | 20,417 | 203 | 82.9% |
| Ranibizumab | generic | 4,862 | 119 | 97.4% |
| Mvasi | brand | 4,508 | 542 | 27.9% |
| Aflibercept | generic | 2,772 | 227 | 97.3% |
| Eylea Hd | brand | 1,091 | 411 | 66.8% |
| Zirabev | brand | 605 | 53 | 81% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Zaltrap reports
How many adverse event reports has FDA received for Zaltrap?
1,227 reports list Zaltrap as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 22 of them arrived in the latest 12 months. Another 59 list it only as a concomitant medication.
What reactions are recorded in Zaltrap reports?
diarrhoea (13.9%), hypertension (10.8%), neutropenia (7.9%), asthenia (5.3%) and proteinuria (5.1%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Zaltrap was responsible.
How serious are the reports?
93.3% are marked serious by the reporter. Among the outcomes recorded, 16% of reports include death and 46% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (56.8%), other health professional (23.1%) and pharmacist (15.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Zaltrap rising?
22 reports in the 12 months to June 2026, up 57% from 14 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Zaltrap was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Zaltrap?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zaltrap as a suspect or interacting product; reports listing it only as a concomitant medication (59) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.